Alecensa 150MG 240S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTKG
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $56,058
Award facts
- Contract value 100% obligated
- $56,057.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $56,057.84 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 240 units of Alecensa 150mg. This delivery order, issued on January 14, 2026 with an ultimate completion date of January 26, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with this delivery order representing one of numerous awards issued by the Defense Logistics Agency's Medical Supply Chain division. The contractor's product portfolio encompasses branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, with Alecensa—an oncology treatment—aligning with the company's established capability to distribute specialized pharmaceutical products to support Department of Defense healthcare operations globally. The underlying IDC, valued at approximately $500 million with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as a key provider within the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FBTKG?
SPE2DR26FBTKG was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FBTKG worth?
The government has obligated $56,058 on SPE2DR26FBTKG.
Is contract SPE2DR26FBTKG an order under another contract?
Yes. SPE2DR26FBTKG is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTKG competed?
The extent of competition for SPE2DR26FBTKG was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award